A supplier once put an analyser in front of a clinic manager I was advising and slid a single number across the table: zero. No capital cost, no purchase order to defend, results in the room from that afternoon. She was delighted. The finance director was delighted. The device was installed inside a fortnight, and for about three months everyone believed they had won.
Then the reagent invoices started. Then the controls. Then a service visit that was not quite covered by the plan they thought they had signed. Then the morning a box of cartridges went into the clinical waste because a lot had expired in the fridge before throughput ever caught up with the vendor's forecast. Eighteen months in, the free analyser was quietly one of the larger recurring lines in the department, and walking away from it meant unpicking a contract, revalidating, retraining every operator and rebuilding the data feed. It was free the way a printer is free.
That experience is the argument of this piece in miniature. The capital price of a point-of-care analyser is usually the least important number in the deal. Procurement that fights over the sticker is often fighting over the wrong figure. The money lives downstream, in reagents, controls, calibrators, external quality assessment, service, connectivity, wastage and staff time, and across a contract term that in the NHS often runs five to fifteen years it recovers the vendor's margin many times over. Buy on total cost of ownership and cost per reportable result, or you will buy badly and feel clever doing it.
Why "free" is a pricing strategy, not a gift
Reagent rental and managed-service contracts are ordinary commercial models in in-vitro diagnostics, and there is nothing underhand about them. The vendor places the analyser at low or no capital cost and recovers its investment through the consumables and service you buy over the term. It is the razor-and-blades model, and diagnostics is close to its purest expression. The giants of the field, Roche, Abbott, Siemens and Beckman Coulter, all run placements that lock in years of reagent revenue on a sticky installed base. Reagents and consumables are the largest single revenue segment in the whole IVD market, around two thirds of it, which is precisely why an analyser can be given away and still be a very good business. The hardware is the hook. The consumable is the business.
The reason this matters to a buyer is not that the model is unfair. It is that the model deliberately moves the cost out of the one number your finance process scrutinises hardest, the capital price, and into a stream of smaller recurring numbers that no single approval ever examines together. A capital purchase gets a business case, a committee and a challenge. A monthly reagent order gets a signature. NHS managed-service deals are billed as a fixed monthly or quarterly charge, sometimes as a flat cost per test, precisely so a trust can budget, and precisely where the aggregate is hardest to see. The economics of the device are decided in the place your governance is weakest, by default, months after the machine arrived, when nobody in the room remembers it as a purchasing decision at all.
I have watched capable finance teams win a hard fight over three thousand pounds of capital and then wave through, unexamined, a consumables commitment worth many times that across the term. The rigour was real. It was pointed at the wrong number. That is the trap in one sentence: the scrutiny is fierce, and it lands nowhere near the money.
The hardware is the hook and the consumables are the business, and the consumable stream is priced in exactly the place your governance looks least closely.
So the discipline is simple to state and hard to practise. Never let the capital price anchor the decision. Treat it as one line among many, and usually a small one.
The lines below the waterline
Once you stop staring at the sticker, the real cost structure comes into view. Most of it is invisible on day one, which is exactly why it survives the buying decision.
Reagents and consumables
This is the engine of the annuity. Every reportable result burns a cartridge, a strip or a reagent pack, and the price per test is where the vendor makes its return. A low headline price is very often mirrored by a high consumable price, because the two are set together in the same negotiation. The figure that actually governs your budget is cost per test multiplied by realistic annual volume, not the machine's face value. To put a real number on how much a single test carries once everything is loaded in, the PACE trial costed one CRP point-of-care run at £11.31, a trial figure rather than a guaranteed procurement price, but a useful order of magnitude. Whether that is money well spent depends on what the result changes, which is the honest question to put to every test on the menu.
Controls, calibrators and EQA
Quality is not free and is never optional. Internal quality control materials are consumed every day the device runs, calibrators on the schedule the method dictates, and external quality assessment fees, through UK NEQAS, WEQAS or an equivalent scheme, recur every year for every analyte in scope. These are the costs of being allowed to trust a result, and they scale with the number of analytes and the QC frequency your risk assessment demands. A cheaper device that measures more analytes can carry more quality cost, not less.
Cartridge wastage and short shelf life
Unit-use consumables carry expiry dates, and reagent packs, once opened, have on-board stability measured in days or weeks. A device sized for a busy clinic and placed in a quiet one throws away reagent it never used. Wastage is a real cost that vendor forecasts rarely dwell on, because the vendor is paid whether the cartridge produces a result or a bin liner. Low, lumpy or seasonal throughput turns a good per-test price into a bad one, and in my experience it is one of the most common ways a placement deal goes wrong.
Service, maintenance and downtime
Service contracts are a recurring line in their own right, and coverage varies enormously between an all-inclusive plan and a bare warranty that bills for parts and visits. Downtime carries its own cost that never lands on an invoice. When the only analyser is dead, the work goes to the main laboratory, to a courier, or to a send-away with a turnaround that changes the clinical decision. A cheaper device with worse uptime can cost more in disruption than it ever saved in capital.
Connectivity and data
A result a clinician cannot see safely in the record is only half a result. Getting numbers off the device and into the patient record involves interfacing effort, sometimes licence fees, and the standing cost of keeping that feed alive through software updates on both sides. Some low-capital placements quietly assume manual transcription, which is often the most expensive and least safe option once you count the staff time and the transcription errors it invites.
Staff time
The most consistently ignored line is people. Every QC run, every calibration, every maintenance task, every competency assessment and every EQA return is someone's paid time. It shows on no purchase order and is rarely modelled, yet across a fleet and a five-year term it can be one of the largest costs in the whole exercise. A device that demands more manual QC or fiddlier maintenance is quietly spending your establishment.
The crossover: why cheap on day one is dear by year five
Put these lines on a timeline and the picture inverts. Take two analysers. Device A is placed free but carries a high per-test consumable price with modest QC and service costs. Device B costs a real capital sum up front, a few thousand pounds, but its consumables and service are cheaper. On day one, A wins. It keeps winning for a while. Then the cumulative curves cross.
The crossover date depends entirely on volume, and that is the whole point. At high throughput the per-test premium on the free device dominates and the crossover comes early. At low throughput, wastage and fixed QC costs punish you instead. There is no single right answer, which is exactly why the sticker cannot be the answer. The only honest way to compare two offers is to model total cost of ownership across the realistic life of the contract, at your real volume, and divide it by the number of results you will actually report.
Cost per reportable result is the only honest comparator
This is not a theoretical plea. When a hospital laboratory actually did it, rebuilding its analyser tender around cost per reportable test rather than the capital price of the box, and pricing in reagents, calibrators, consumables and the hidden operational costs, the winning maintenance-free reagent-rental bid came out 47.4 percent cheaper per reportable test than the equipment it replaced. The same testing, the same volumes, a different way of counting, and nearly half the cost per result. That is the size of the prize sitting inside a number most procurement never calculates.
The same study shows why you cannot shortcut it with a rule of thumb. The saving was wildly uneven across the menu: about 22 percent on albumin, 79 percent on amylase, and for one analyte, lipase, no saving at all because the price was already keen. If the discount on your busiest analyte is small and the discount on one you barely run is huge, the average tells you nothing useful. You have to model your own menu, at your own volumes.
Cheaper is not the automatic answer either. A UK cost-minimisation analysis of point-of-care versus laboratory testing in the NHS Health Check found only a modest saving, around £29 per hundred patients invited, and it hinged on point-of-care testing sparing the missed appointments the laboratory pathway invites. A wider systematic review of the health economics of point-of-care testing reached the honest conclusion that the evidence is mixed and context is everything. Sometimes near-patient testing saves money, sometimes it does not, and the deciding factor is almost always the setting and the volume, not the technology. Which is simply the case for building the model rather than trusting the brochure.
The cheapest device on day one is very often the most expensive over five years. The figure that should settle it is cost per reportable result.
Lock-in: the price of having chosen badly
There is one line that appears in no model, and it is the switching cost. A placed analyser ties you to that vendor's consumables, its controls, its service and its data feed. When the contract renews, your negotiating position is weak, because leaving means fresh validation, competency sign-off for every operator again, a new EQA arrangement and a rebuilt connection to the record. This is well understood on both sides of the table. The generous day-one offer and the firm renewal tend to go together, the first making the second easier to hold, and on a term that can run to fifteen years the renewal is where much of the real money is quietly decided.
So the shape of the contract matters as much as its price. A long exclusive term with punitive exit terms is worth less than a shorter one at a slightly higher headline, because optionality has value and lock-in has a cost. Procurement that reads only the per-test figure and not the clause on minimum volumes, term length and exit is reading half the contract.
What this means for your service
None of this argues against placement deals. Well chosen, at the right volume, on the right contract, a low-capital placement can be genuinely the best value on the table. It argues against choosing on the wrong number. The discipline, in the order I would apply it:
- Build a five-year total cost of ownership model before you decide. Capital or placement fee, consumables at realistic volume, controls, calibrators, EQA fees, service, connectivity, training and staff time. Put every line in, including the ones you have to estimate.
- Reduce every offer to cost per reportable result. This single figure is the honest comparator between a free device and a bought one, and it drags the per-test premium the capital price was hiding into the light.
- Model your real volume, then stress it. Run the numbers at expected, low and high throughput. Wastage punishes the quiet clinic; per-test price punishes the busy one. Know which risk you are carrying.
- Put the hidden-cost questions to the vendor directly. What is the per-test price, and does it move with volume? What is the on-board stability once a pack is opened? Which controls and calibrators are mandated, and at what cost? What EQA is required? What exactly does the service plan cover, and what does downtime cost me? What are the connectivity fees? What is the minimum-volume commitment, the term and the exit?
- Read the shape of the contract, not just the price. Term length, minimum volumes, price-escalation clauses and exit terms are where lock-in lives. Prefer optionality and price it in.
- Count the staff time honestly. QC, maintenance, competency and EQA are recurring labour. A device that needs more of your people is more expensive, whatever the invoice says.
If you want to run this properly, our procurement support builds the model with you and sits on your side of the table when the questions get awkward. We publish a procurement matrix template in the resource library so you can score competing offers on total cost rather than sticker price, and our training, including the free POCT Fundamentals course, covers the QC and competency costs the model has to include. Knowing what each analyte actually demands in controls and EQA is part of the same discipline.
The number that matters
The next time a supplier slides a zero across the table, thank them, and then ignore it. Ask instead what a trustworthy result will cost you every single time you produce one, for the next five years, at the volume you actually run. That is the number that decides whether the deal is good. The sticker price was never the price. It was the bait.
Sources and notes
The figures here are drawn from NHS procurement guidance, peer-reviewed and health-technology-assessment sources, and published market data. The 47.4 percent figure comes from a single-hospital biochemistry tender and is used to show the size of the gap between capital-price and cost-per-reportable-test procurement, not as a guaranteed saving anyone can expect. The reagents share of the IVD market is a market-research estimate that varies by source and year. The iceberg and five-year crossover diagrams are schematic illustrations of the argument rather than measured datasets; the real crossover depends entirely on your volume and contract.
- NHS Supply Chain. Managed services for diagnostics. Contracts typically five to fifteen years, billed as fixed unitary or cost-per-test charges.
- Kulshrestha MR, Tiwari V, Singh S, Pathak AK. An approach to include the cost of consumables in biochemistry analyzer procurement on the reagent rental model alleviates hidden expenses. EJIFCC, 2024;35(3):182 to 188.
- PACE trial. Cost-effectiveness of C-reactive protein point-of-care testing in acute exacerbations of COPD. CRP point-of-care test costed at £11.31 per test, 2024.
- El-Osta A and colleagues. Does use of point-of-care testing improve cost-effectiveness of the NHS Health Check programme? A cost-minimisation analysis. BMJ Open, 2017.
- PharmacoEconomics Open. Health economic evidence of point-of-care testing: a systematic review, 2020.
- Grand View Research. In-vitro diagnostics market report. Reagents and consumables the largest revenue segment.
- MedTech Terms. The razor and razor-blade model in medical technology.
- UK NEQAS. Point-of-care testing external quality assessment. Recurring annual per-analyte scheme fees.